WO2014144815A3 - Vectors and methods to treat ischemia - Google Patents

Vectors and methods to treat ischemia Download PDF

Info

Publication number
WO2014144815A3
WO2014144815A3 PCT/US2014/029386 US2014029386W WO2014144815A3 WO 2014144815 A3 WO2014144815 A3 WO 2014144815A3 US 2014029386 W US2014029386 W US 2014029386W WO 2014144815 A3 WO2014144815 A3 WO 2014144815A3
Authority
WO
WIPO (PCT)
Prior art keywords
vectors
methods
treat ischemia
nucleic acid
disclosure relates
Prior art date
Application number
PCT/US2014/029386
Other languages
French (fr)
Other versions
WO2014144815A2 (en
Inventor
Jan Nolta
Karen PEPPER
Fernando FIERRO
Gerhard Bauer
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/844,138 external-priority patent/US20140065110A1/en
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to US14/776,673 priority Critical patent/US9663564B2/en
Priority to AU2014228526A priority patent/AU2014228526A1/en
Priority to EP14765183.0A priority patent/EP2968609A4/en
Publication of WO2014144815A2 publication Critical patent/WO2014144815A2/en
Publication of WO2014144815A3 publication Critical patent/WO2014144815A3/en
Priority to US15/607,638 priority patent/US20180022787A1/en
Priority to AU2019201858A priority patent/AU2019201858A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

This disclosure relates to vectors, isolated cells, compositions, and methods for the treatment of critical limb ischemia and associated disorders. One aspect of the disclosure relates to a vector comprising a nucleic acid encoding a 165A isoform VEGF protein and a promoter that regulates expression of the nucleic acid encoding the VEGF.
PCT/US2014/029386 2012-08-31 2014-03-14 Vectors and methods to treat ischemia WO2014144815A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US14/776,673 US9663564B2 (en) 2013-03-15 2014-03-14 Vectors and methods to treat ischemia
AU2014228526A AU2014228526A1 (en) 2013-03-15 2014-03-14 Vectors and methods to treat ischemia
EP14765183.0A EP2968609A4 (en) 2013-03-15 2014-03-14 Vectors and methods to treat ischemia
US15/607,638 US20180022787A1 (en) 2012-08-31 2017-05-29 Vectors and methods to treat ischemia
AU2019201858A AU2019201858A1 (en) 2013-03-15 2019-03-18 Vectors and methods to treat ischemia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/844,138 US20140065110A1 (en) 2012-08-31 2013-03-15 Genetically modified msc and therapeutic methods
US13/844,138 2013-03-15
USPCT/US2013/057721 2013-08-30
PCT/US2013/057721 WO2014036524A2 (en) 2012-08-31 2013-08-30 Genetically modified msc and therapeutic methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/844,138 Continuation-In-Part US20140065110A1 (en) 2012-08-31 2013-03-15 Genetically modified msc and therapeutic methods

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/776,673 A-371-Of-International US9663564B2 (en) 2012-08-31 2014-03-14 Vectors and methods to treat ischemia
US15/607,638 Continuation US20180022787A1 (en) 2012-08-31 2017-05-29 Vectors and methods to treat ischemia

Publications (2)

Publication Number Publication Date
WO2014144815A2 WO2014144815A2 (en) 2014-09-18
WO2014144815A3 true WO2014144815A3 (en) 2014-11-06

Family

ID=51538378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/029386 WO2014144815A2 (en) 2012-08-31 2014-03-14 Vectors and methods to treat ischemia

Country Status (3)

Country Link
EP (1) EP2968609A4 (en)
AU (2) AU2014228526A1 (en)
WO (1) WO2014144815A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026288A1 (en) * 2003-01-23 2005-02-03 Harms Jerome S. Inducible protein expression system
US20070010469A1 (en) * 2000-06-02 2007-01-11 Chan Vivien W Gene products differentially expressed in cancerous cells III
US20090155220A1 (en) * 2005-10-20 2009-06-18 Caritas St. Elizabeth's Medical Center Of Boston Use of Bone-Marrow Derived Stem Cells to Treat Ischemia
US20110201118A1 (en) * 2010-06-14 2011-08-18 Iowa State University Research Foundation, Inc. Nuclease activity of tal effector and foki fusion protein
US20110256160A1 (en) * 2008-09-02 2011-10-20 Moran Meiron Adherent cells from placenta tissue and use thereof in therapy
US20120076763A1 (en) * 2009-04-30 2012-03-29 The Regents Of The University Of California Combination anti-hiv vectors, targeting vectors, and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010469A1 (en) * 2000-06-02 2007-01-11 Chan Vivien W Gene products differentially expressed in cancerous cells III
US20050026288A1 (en) * 2003-01-23 2005-02-03 Harms Jerome S. Inducible protein expression system
US20090155220A1 (en) * 2005-10-20 2009-06-18 Caritas St. Elizabeth's Medical Center Of Boston Use of Bone-Marrow Derived Stem Cells to Treat Ischemia
US20110256160A1 (en) * 2008-09-02 2011-10-20 Moran Meiron Adherent cells from placenta tissue and use thereof in therapy
US20120076763A1 (en) * 2009-04-30 2012-03-29 The Regents Of The University Of California Combination anti-hiv vectors, targeting vectors, and methods of use
US20110201118A1 (en) * 2010-06-14 2011-08-18 Iowa State University Research Foundation, Inc. Nuclease activity of tal effector and foki fusion protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2968609A4 *

Also Published As

Publication number Publication date
WO2014144815A2 (en) 2014-09-18
AU2014228526A1 (en) 2015-11-05
EP2968609A2 (en) 2016-01-20
AU2019201858A1 (en) 2019-04-11
EP2968609A4 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
MX2018005829A (en) Compositions for treating the hair.
EP3221453A4 (en) Aav vectors targeted to the central nervous system
MX2021007663A (en) Target-tissue-specific antigen-binding molecule.
MD20170035A2 (en) Compositions and methods of use for treating matabolic disorders
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
WO2015010135A3 (en) Compositions for modulating tau expression
EA201691594A1 (en) CYCLOPROPYLAMINES AS LSD1 INHIBITORS
EP3351254A4 (en) Composition for preventing or treating inflammatory diseases, containing, as active ingredient, stem cells overexpressing sod3
MX2018008105A (en) Metalloenzyme inhibitor compounds.
BR112017002781A2 (en) Enhanced expression cassette for packaging and expression of factor viii variants for treatment of hemostasis disorders
WO2014145729A3 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
EA201690007A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
IN2014DN06792A (en)
WO2012118903A3 (en) Sclerostin and dkk-1 bispecific binding agents
PH12015502126A1 (en) Human pac1 antibodies
WO2016164896A3 (en) Modulation of smn expression
EP3393482A4 (en) Therapeutic methods using erythrocytes
WO2013024467A3 (en) Mitochondrial ribosomal proteins as aging regulators
WO2013106273A3 (en) Peptides and methods of using same
WO2014151982A3 (en) Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
WO2018138032A3 (en) NKp46 BINDING AGENTS
ZA201803551B (en) Personal care composition comprising taurine, arginine, glycine
EP3331545A4 (en) Hemichannel extracellular-domain specific agents for treating sepsis
WO2014186450A3 (en) Highly potent inhibitors of porcupine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14765183

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14776673

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2014765183

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014228526

Country of ref document: AU

Date of ref document: 20140314

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14765183

Country of ref document: EP

Kind code of ref document: A2